Original Publication Date: 1 October, 2015
Publication / Source: Epigenomics
Authors: James N Lowder, Pietro Taverna & Jean-Pierre J Issa
Epigenetic changes, similar to mutations, have been implicated in the malignant behavior of tumors. Although the rate of acquisition of somatic mutations plateaus early in mammalian life, epigenetic drift of the genome steadily increases with age [1,2]. DNA methylation of CpG sites in gene promoters is a physiologic process in silencing genes important for development. This process is usurped in cancer and stable aberrant methylation maintaining reduced expression of genes in malignant cells is essential to their success.